Compare Amphastar Pharmaceuticals Inc (AMPH) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

SPUS, a US stock, trades at $57.78, up 0.56% today, with a bullish technical signal from moving averages and neutral oscillators. Recent corporate actions include quarterly dividends of $0.03, with the latest paid on June 26, 2026. Key financial ratios like P/E and P/S are unavailable in the provided data, limiting fundamental depth. Support and resistance levels cluster near the current price, indicating potential volatility.

The outlook for SPUS is cautiously optimistic, driven by technical strength and dividend consistency, but lacks clear fundamental metrics. Risks include market volatility and reliance on broader equity trends. Investment opportunity hinges on technical momentum, while the absence of valuation data warrants careful analysis for long-term holders.